Post vaccination immunological response and immune monitoring for SARS-CoV-2
Not Applicable
- Registration Number
- CTRI/2021/08/035338
- Lead Sponsor
- Medanta Institute of Education and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Healthy adult (18-60 years) individuals receiving anti SARS CoV 2 vaccination, irrespective of their pre-vaccination serological status, providing informed consent for sampling.
Exclusion Criteria
All individuals <18 and >60 years.
Non consenting for sampling
Individuals who develop COVID 19 infection during study period will be excluded from study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of quantitative (titer) IgG neutralizing antibody as well the generation of memory T cell responses to viral antigens will be measured in the studyTimepoint: Visit1: Blood collection and 1st dose of vaccine <br/ ><br>Visit2: Blood collection at 15th day post 1st dose of vaccine <br/ ><br>Visit3: Blood collection and 2nd dose of vaccine <br/ ><br>Visit 4: Blood collection at 15th day post 2nd dose <br/ ><br>Visit 5:Blood collection 6 month post first dose
- Secondary Outcome Measures
Name Time Method Correlation of these parameters with incidence of infection for a follow up period of 6 months will provide correlates of protection achieved from vaccination vis-a-vis natural infectionTimepoint: 6 month follow up <br/ ><br>1 month for statistical analysis and manuscript